Intravascular Radiofrequency Ablation of Sympathetic Nerves for the Treatment of Hepatocellular Carcinoma

Recruiting now · Not applicable

Conditions studied: Hepatocellular Carcinoma

In brief

Patients who met the inclusion criteria were treated with endovascular radiofrequency ablation and desympathetic nerve surgery. After enrollment, endovascular radiofrequency ablation and desympathetic surgery were performed. After radiofrequency ablation, the safety and efficacy of follow-up treatment will be carried out every 1 month or so, including blood routine, liver and kidney function, tumor indicators, abdominal CT/magnetic resonance, etc.

Key facts

Study ID

NCT06694636

Run by

Zhongda Hospital

People needed

5

Starts

2024-02-01

Expected to finish

2026-02-01

Last updated by the study team

2024-11-19

Who can join

Age: 25 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Clinically or pathologically confirmed hepatocellular carcinoma (HCC)
• Locally progressed or distant metastatic unresectable advanced HCC
• Progressed after second-line therapy
• Agree to participate in the study and sign the informed consent form

You may not qualify if…

• Not suitable for ablation surgery
• Pregnant, lactating and planning to become pregnant
• Orthostatic hypotension
• Mixed liver cancer
• Intestinal obstruction
• Obvious bleeding tendencies and hematologic diseases
• Acute or severe systemic infection;
• Stroke or transient ischemic attack (TIA) within two weeks;
• Acute coronary syndrome within two weeks;
• Evaluated to be not suitable for this trial by investigators

Where it is running

• Zhongda Hospital — Nanjing, Jiangsu, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.